

People who beat cancer, or have neurodegenerative conditions that are very slow to progress, may harbor naturally occurring protective antibodies that make them more resilient against these devastating diseases. Alchemab sequences the B cells of these individuals, uses AI to identify groups of related antibodies across the resilient population, finds the binding targets of these antibodies, and uses that information to design treatments that could help other patients fight solid tumors, infections, or Alzheimer’s.
In The Media
Explore Companies

Grove Biopharma
Putting protein-like drugs inside cells to fight cancer and neurodegeneration

Syntax Bio
Programming stem cells to differentiate into desired cell types, faster

Fable Therapeutics
Using state-of-the-art machine learning models to create custom-build protein drugs

Nilo Therapeutics
Mapping the brain-body axis to achieve proper immune balance